Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by wolfy2424on Dec 16, 2016 5:04pm
430 Views
Post# 25612625

Can some of you PLI vets clarify this please?

Can some of you PLI vets clarify this please?I am a PLI long share holder but would like some clarification - the SA article brings some interesting points as well as the email Pierre sent to Scott recently - I have highlighted the points below for clarification.  Let's say for a moment that I am playing devils advocate here to gather information and clarify some things

Email from Pierre to Scott:


 
  PBI-4050 works !!!! works in humans !!! not just in rats and mice  !!!! Oh my God, clinical trials will cost a lot of money, we will need to partner….
Euh hello ? of course we will partner but not to finance $8 - $10 million worth of clinical trials in 2017 !!!!

And of course regional partnering that make sense is our first priority.

my question - At this point PBI is not guaranteed in anyway to be a success yet this is Pierre's first point in his email - it may work and still not get approval.   A partnership would be nice however - how realistic is this really?

 
  Plasmiogen works !!!! no surprise one would say, yet it certainly work better than originally anticipated…resolving old lesions in minutes… !!!!
Oh and we now know that we can treat hundreds of thousands of patients with plasminogen, staring with severe burns !!!! 20,000 of them in the USA !
That alone is 5-6 times more patients than the congenital deficiency patient population….
What is wrong with patient in shock like severe burn patients…Plasminogen is down….what do know from our phase II/III and animal studies…bring Pg up and the patients will heal better…

Plasminogen may work but according to the SA article which sites data the value of the market for plasminogen has been greatly overvalued by PLI.  Let's say that it the PD market has been overvalued and they are not really at their target - this would mean that the next source of revenue would come from burn victims or wound victims and that is a longer time frame - possilby 2019 or 2020?  Can anyone confirm this?  Have we truly been duped by PL about how much this is worth? 
 
  We have existing capacity that can enable sales north of US$500 M between Laval and Winnipeg.  But we think that Pg sales could be so big we are considering future capacity…something

This does sound very speculative - does he have numbers to back this up?  If yes - the timeframe for this could be multiple years away - more time that people will grow impatient 



  We burn cash and we have cash,  we burn enough not too much, well enough to generate catalysts – increase revenue – deals.
We have never been in such a positive cash position in our corporate history….and people are nervous.
 
They are nervous perhaps because according to the 2011 report revenue from Plasminogen was only 24 months away - this may be why investors are growing impatient and worried - I know personally I would rather have the truth than BS


  The only thing that makes me nervous is being acquired at below $10 per share because many shareholders want to be cashing in and don’t think we can get much higher.

At this point I think many people would sell for under $5 



I would also like to see PLI respond to certain points made in the article - including the yields and clarifying which numbers are accurate and why there is such a discrepency in 3 different reports 




Bullboard Posts